Erasca (ERAS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Erasca

NasdaqGS•Healthcare•Biotechnology

$14.77-0.57(-0.04%)Market closed

Market Cap

$4.60B

P/B

12.7x

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

How this company scores

WeakMetricSide Score: 34/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (5/25).

Profitability5/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 12.7x5y range 0.9x – 12.7x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $4.60B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-302.68M
TTM Op. Income: $-302.68M
Q. Op. Income: $-47.62M
TTM Net Income: $-287.22M
Q. Net Income: $-44.08M
EPS: $-0.14
Shares Out.: $311.34M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-302.68M and TTM operating income of $-302.68M show growth is flowing through to the bottom line. However, net income is negative at $287.22M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -4761900000.0%
Net Margin: -4407900000.0%

Op. margin of -4761900000.0% is down 949400000.0% YoY — costs are rising relative to revenue. Net margin at -4407900000.0% Over the past year, operating margin is down 25% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 12.7x

P/S of 0.0x and P/B of 12.7x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $435.05M
Cash: $42.54M
Long-Term Debt: N/A
Book Value: $361.87M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-27.27M
TTM Free Cash Flow: $-98.08M
FCF Margin: N/A
FCF / Net Income: 0.3

TTM FCF of $-98.08M on $-27.27M in operating cash flow. The FCF / Net Income ratio of 0.3x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 1% — a weakening trend.